Skip to content

Other Working Capital at other companies

Amgen logo
AmgenAMGN
$67M+34.0%
Incyte logo
IncyteINCY
-$12.77M-141%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$1M
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$1M-200%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$2.15M-410%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$5K

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.29B+57.5%

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s other working capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s other working capital?
Arcutis Biotherapeutics, Inc. (ARQT) reported other working capital of -$214K in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s other working capital changed year-over-year?
Arcutis Biotherapeutics, Inc.'s other working capital decreased by 296.3% year-over-year, from -$54K to -$214K.
What does other working capital mean?
Net change in working capital items not separately classified — a residual balancing item.